{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.28","value":"0.00"},{"groupId":"OG001","spread":"9.86","value":"0.10"},{"groupId":"OG002","spread":"9.33","value":"0.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"310"},{"groupId":"OG001","value":"305"},{"groupId":"OG002","value":"301"}],"units":"Participants"}],"title":"CP: Change at Day 1, Cycle 2: Sitting DBP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.18","value":"-0.50"},{"groupId":"OG001","spread":"10.84","value":"0.50"},{"groupId":"OG002","spread":"9.69","value":"1.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"305"},{"groupId":"OG001","value":"299"},{"groupId":"OG002","value":"295"}],"units":"Participants"}],"title":"CP: Change at Day 1, Cycle 3: Sitting DBP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.48","value":"-0.10"},{"groupId":"OG001","spread":"10.89","value":"-0.50"},{"groupId":"OG002","spread":"10.19","value":"-0.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"287"},{"groupId":"OG001","value":"291"},{"groupId":"OG002","value":"289"}],"units":"Participants"}],"title":"CP: Change at Day 1, Cycle 4: Sitting DBP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.36","value":"-2.20"},{"groupId":"OG001","spread":"10.74","value":"-1.30"},{"groupId":"OG002","spread":"10.54","value":"-0.90"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"266"},{"groupId":"OG002","value":"253"}],"units":"Participants"}],"title":"MP/OP: Change at Day 1, Cycle 1: Sitting DBP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.04","value":"-2.10"},{"groupId":"OG001","spread":"10.57","value":"-1.80"},{"groupId":"OG002","spread":"5.69","value":"-9.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"249"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"MP/OP: Change at Day 15, Cycle 1: Sitting DBP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.29","value":"-1.70"},{"groupId":"OG001","spread":"11.24","value":"-1.80"},{"groupId":"OG002","spread":"6.03","value":"-8.30"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"233"},{"groupId":"OG001","value":"249"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"MP/OP: Change at Day 29, Cycle 1: Sitting DBP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.26","value":"-2.30"},{"groupId":"OG001","spread":"10.63","value":"-1.70"},{"groupId":"OG002","spread":"10.67","value":"-0.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"247"},{"groupId":"OG002","value":"226"}],"units":"Participants"}],"title":"MP/OP: Change at Day 1, Cycle 2: Sitting DBP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.71","value":"-2.00"},{"groupId":"OG001","spread":"10.82","value":"-2.40"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"236"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"MP/OP: Change at Day 15, Cycle 2: Sitting DBP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.86","value":"-2.60"},{"groupId":"OG001","spread":"10.16","value":"-1.90"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"225"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"MP/OP: Change at Day 29, Cycle 2: Sitting DBP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.36","value":"-0.70"},{"groupId":"OG001","spread":"12.45","value":"0.00"},{"groupId":"OG002","spread":"10.00","value":"0.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"116"},{"groupId":"OG002","value":"120"}],"units":"Participants"}],"title":"Change at EOT : Sitting DBP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.91","value":"2.30"},{"groupId":"OG001","spread":"15.32","value":"0.70"},{"groupId":"OG002","spread":"14.00","value":"1.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"310"},{"groupId":"OG001","value":"305"},{"groupId":"OG002","value":"301"}],"units":"Participants"}],"title":"CP: Change at Day 1, Cycle 2: Sitting SBP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.00","value":"1.50"},{"groupId":"OG001","spread":"15.48","value":"-0.30"},{"groupId":"OG002","spread":"14.80","value":"1.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"305"},{"groupId":"OG001","value":"299"},{"groupId":"OG002","value":"295"}],"units":"Participants"}],"title":"CP: Change at Day 1, Cycle 3: Sitting SBP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.60","value":"1.00"},{"groupId":"OG001","spread":"16.75","value":"0.10"},{"groupId":"OG002","spread":"15.61","value":"0.60"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"287"},{"groupId":"OG001","value":"291"},{"groupId":"OG002","value":"289"}],"units":"Participants"}],"title":"CP: Change at Day 1, Cycle 4: Sitting SBP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.12","value":"-1.80"},{"groupId":"OG001","spread":"16.64","value":"-1.60"},{"groupId":"OG002","spread":"14.81","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"253"},{"groupId":"OG001","value":"266"},{"groupId":"OG002","value":"253"}],"units":"Participants"}],"title":"MP/OP: Change at Day 1, Cycle 1: Sitting SBP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.37","value":"-1.10"},{"groupId":"OG001","spread":"16.44","value":"-3.20"},{"groupId":"OG002","spread":"10.21","value":"-4.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"249"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"MP/OP: Change at Day 15, Cycle 1: Sitting SBP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.81","value":"-2.20"},{"groupId":"OG001","spread":"15.93","value":"-2.80"},{"groupId":"OG002","spread":"8.14","value":"-9.30"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"233"},{"groupId":"OG001","value":"249"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"MP/OP: Change at Day 29, Cycle 1: Sitting SBP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.16","value":"-1.20"},{"groupId":"OG001","spread":"15.46","value":"-0.60"},{"groupId":"OG002","spread":"14.43","value":"-0.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"247"},{"groupId":"OG002","value":"226"}],"units":"Participants"}],"title":"MP/OP: Change at Day 1, Cycle 2: Sitting SBP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.44","value":"-2.10"},{"groupId":"OG001","spread":"16.20","value":"-3.90"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"219"},{"groupId":"OG001","value":"236"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"MP/OP: Change at Day 15, Cycle 2: Sitting SBP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.79","value":"-2.70"},{"groupId":"OG001","spread":"15.28","value":"-2.90"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"225"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"MP/OP: Change at Day 29, Cycle 2: Sitting SBP"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.96","value":"1.70"},{"groupId":"OG001","spread":"17.56","value":"-1.00"},{"groupId":"OG002","spread":"16.69","value":"2.90"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"137"},{"groupId":"OG001","value":"116"},{"groupId":"OG002","value":"120"}],"units":"Participants"}],"title":"Change at EOT: Sitting SBP"}],"denoms":[{"counts":[{"groupId":"OG000","value":"318"},{"groupId":"OG001","value":"317"},{"groupId":"OG002","value":"316"}],"units":"Participants"}],"description":"Vital signs included blood pressure and pulse rate. Blood pressure included sitting diastolic blood pressure (DBP) and sitting systolic blood pressure (SBP). MP is applicable only for two arms 'Chemotherapy followed by Avelumab' and 'Chemotherapy + Avelumab followed by Avelumab'. OP is applicable only for third arm 'Chemotherapy followed by Observation'. Category titles 'MP/OP' imply which ever phase was applicable for the respective reporting arms.","dispersionType":"Standard Deviation","groups":[{"description":"In chemotherapy phase (CP),based on investigator's decision,participants received either:paclitaxel 175 milligrams per square meter (mg/m2) intravenous (IV) infusion,followed by carboplatin dose at area under curve (AUC) 5 or 6,IV infusion (carboplatin dose (mg) = Target AUC (mg\\*min/mL) x (glomerular filtration rate\\[GFR\\] mL/min + 25),and maximum carboplatin dose = target AUC x (150 mL/min) on Day 1 of Cycles 1 to 6; or Paclitaxel 80 mg/m2 IV infusion over 1 hour on Days 1, 8, and 15, along with carboplatin dose at AUC 5 or 6, IV infusion over 1 hour on Day 1 of Cycle 1 to 6 (1 cycle=21 days). After completion of CP, participants without evidence of disease progression, received avelumab 10 mg/kg, over 1 hour IV infusion,once every 2 weeks on Days 1, 15, and 29 (1 cycle=42 days) in maintenance phase (MP) until confirmed progressive disease,unacceptable toxicity, or withdrawal of consent, or a maximum duration of 24 months. Participants were then followed up to a maximum of 36 months.","id":"OG000","title":"Chemotherapy Followed by Avelumab"},{"description":"In CP, based on investigator's decision, participants received either:paclitaxel 175 mg/m2,IV,followed by carboplatin dose at AUC 5 or 6,IV (carboplatin dose \\[milligrams\\](mg) = Target AUC (mg\\*min/mL) x GFR mL/min + 25),and maximum carboplatin dose = target AUC x (150 mL/min) on Day 1 of Cycles 1 to 6;or Paclitaxel 80 mg/m2 IV infusion over 1 hour on Days 1, 8, and 15, along with carboplatin dose at AUC 5 or 6, IV infusion over 1 hour on Day 1 of Cycle 1 to 6 along with Avelumab 10 mg/kg administered as a 1-hour IV infusion once every 3 weeks for Cycle 1 to 6 ( 1 cycle=21 days).After completion of CP, participants without evidence of disease progression, received Avelumab IV, 10 mg/kg, once every 2 weeks on Days 1, 15, and 29 ( 1 cycle=42 days) in MP until confirmed progressive disease (PD), unacceptable toxicity, or withdrawal of consent, or a maximum duration of 24 months. Participants were then followed up to a maximum of 36 months.","id":"OG001","title":"Chemotherapy + Avelumab Followed by Avelumab"},{"description":"In CP, based on investigator's decision, participants received either: paclitaxel 175 mg/m2, IV infusion, followed by carboplatin dose at AUC 5 or 6, IV infusion (carboplatin dose \\[milligrams\\](mg) = Target AUC \\[milligrams\\*minute per milliliter\\] (mg\\*min/mL) x GFR mL/min + 25), and maximum carboplatin dose = target AUC x (150 mL/min) on Day 1 of Cycles 1 to 6; or Paclitaxel 80 mg/m2 IV infusion over 1 hour on Days 1, 8, and 15, along with carboplatin dose at AUC 5 or 6, IV infusion over 1 hour on Day 1 of Cycle 1 to 6. Each cycle was of 21 days (3 weeks). After completion of CP, participants were followed for survival status until death or until study completion, whichever was earlier or a maximum duration of 24 months in observation phase. Participants were then followed up to a maximum of 36 months.","id":"OG002","title":"Chemotherapy Followed by Observation"}],"paramType":"MEAN","populationDescription":"The safety analysis set included all participants who had received at least one dose of study drug. Here \"Overall number of participants analyzed\" signifies participants who were evaluable for this outcome measure and 'Number analyzed' = participants evaluable for this outcome measure at specified rows.","reportingStatus":"POSTED","timeFrame":"Baseline, first 3 months of Chemotherapy Phase (CP): Day 1 of Cycles 2, 3 and 4 (each cycle 21 days); Maintenance/Observation Phase (MP/OP): Days 1, 15 and 29 of Cycles 1 and 2 (each cycle 42 days) and at end of treatment (up to 27 months)","title":"Change From Baseline in Vital Signs - Blood Pressure at Day 1 of Cycles 2, 3, 4 in Chemotherapy Phase; Days 1, 15 and 29 of Cycles 1 and 2 in Maintenance/ Observation Phase and at End of Treatment","type":"SECONDARY","unitOfMeasure":"millimeters of mercury"}